| Literature DB >> 17551491 |
H L Shepherd1, M H N Tattersall, P N Butow.
Abstract
Most cancer patients in westernised countries now want all information about their situation, good or bad, and many wish to be involved in decision-making. The attitudes to and use of shared decision-making (SDM) by cancer doctors is not well known. Australian cancer clinicians treating breast, colorectal, gynaecological, haematological, or urological cancer were surveyed to identify their usual approach to decision-making and their comfort with different decision-making styles when discussing treatment with patients. A response rate of 59% resulted in 624 complete surveys, which explored usual practice in discussing participation in decision-making, providing information, and perception of the role patients want to play. Univariate and multivariate analyses were performed to identify predictors of use of SDM. Most cancer doctors (62.4%) reported using SDM and being most comfortable with this approach. Differences were apparent between reported high comfort with SDM and less frequent usual practice. Multivariate analysis showed that specialisation in breast or urological cancers compared to other cancers (AOR 3.02), high caseload of new patients per month (AOR 2.81) and female gender (AOR 1.87) were each independently associated with increased likelihood of use of SDM. Barriers exist to the application of SDM by doctors according to clinical situation and clinician characteristics.Entities:
Mesh:
Year: 2007 PMID: 17551491 PMCID: PMC2359664 DOI: 10.1038/sj.bjc.6603841
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Treatment decision-making examples.
Demographics of sample
|
|
|
|---|---|
|
| |
| Breast | 308 (51.0) |
| Colorectal | 79 (13.1) |
| Gynaecological | 27 (4.5) |
| Leukaemia/lymphoma | 83 (13.7) |
| Urological | 107 (17.7) |
|
| |
| Medical oncologist | 126 (20.9) |
| Radiation oncologist | 51 (8.4) |
| Surgeon | 354 (58.6) |
| Haematologist | 61 (10.1) |
| Paediatric oncologist | 12 (2.0) |
|
| |
| Male | 544 (83.3) |
| Female | 101 (16.7) |
|
| |
| Australia | 544 (90.4) |
| Other | 58 (9.6) |
|
| |
| <20 h | 170 (31.2) |
| 20 h or more | 375 (68.8) |
|
| |
| Private hospital | 217 (39.8) |
| Public hospital | 165 (30.3) |
| Cancer centre | 43 (7.9) |
| University affiliated | 8 (1.5) |
| Public/private 50/50 | 111 (20.4) |
| Other | 1 (0.2) |
|
| |
| <100 000 | 41 (7.5) |
| 100 000–500 000 | 184 (33.8) |
| >500 000 | 319 (58.7) |
|
| |
| 2 or less | 81 (13.5) |
| 3–6 | 232 (38.8) |
| 7–10 | 147 (24.6) |
| 11–15 | 69 (11.5) |
| 16–20 | 37 (6.2) |
| 21+ | 32 (5.4) |
| Median | 3–6 new patients per month |
| Age (mean) | 50 years (32–79 years) |
| Years qualified (mean) | 26 years (4–56 years) |
Percentages based on valid cases only.
With specified cancer.
Usual approach to decision-making and comfort levels with each approach
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
| Paternalistic (example 1) | 6 (1.0) | 198 (37.1) | 144 (27.0) | 85 (15.9) | 60 (11.3) | 46 (8.6) |
| Information sharing (example 2) | 138 (23.2) | 39 (7.3) | 95 (17.8) | 135 (25.3) | 154 (28.9) | 110 (20.6) |
| Informed (example 3) | 49 (8.2) | 73 (13.7) | 118 (22.1) | 115 (21.5) | 145 (27.2) | 83 (15.5) |
| Shared (example 4) | 372 (62.4) | 11 (2.1) | 23 (4.3) | 49 (9.1) | 133 (24.8) | 320 (59.7) |
| None of these | 1 (0.2) | |||||
| Other | 30 (5.0) |
Amount of information given to new patients
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Extent of the disease | 1 (0.2) | 4 (0.7) | 37 (6.2) | 233 (38.8) | 326 (54.2) | 4.46 (0.658) |
| Details of treatment procedures | 1 (0.2) | 0 (0) | 22 (3.7) | 193 (32.1) | 385 (64.1) | 4.60 (0.578) |
| Benefits of treatment | 1 (0.2) | 0 (0) | 18 (3.0) | 234 (39.1) | 346 (57.8) | 4.54 (0.573) |
| Risks (side effects) of treatment | 1 (0.2) | 2 (0.3) | 36 (6.0) | 237 (39.5) | 324 (54.0) | 4.47 (0.640) |
| Impact of treatment on sexuality | 34 (5.7) | 128 (21.4) | 189 (31.6) | 136 (22.7) | 111 (18.6) | 3.27 (1.158) |
| Changes in appearance due to treatment | 22 (3.7) | 63 (10.5) | 197 (32.9) | 218 (36.4) | 99 (16.5) | 3.52 (1.006) |
| Effects of treatment on mood | 41 (6.8) | 135 (22.5) | 247 (41.1) | 133 (22.1) | 45 (7.5) | 3.01 (1.010) |
| Effects of treatment on family | 51 (8.5) | 179 (29.8) | 223 (37.1) | 107 (17.8) | 41 (6.8) | 2.85 (1.033) |
| Effects of treatment on social activities | 22 (3.7) | 114 (19.0) | 233 (38.8) | 178 (29.7) | 53 (8.8) | 3.21 (0.972) |
| Effects of treatment on patients’ ability to care for themselves at home | 15 (2.5) | 72 (12.0) | 194 (32.4) | 229 (38.2) | 89 (14.9) | 3.51 (0.969) |
| Total information giving score | 37.38 (5.372) |
Perception of patient preferred role
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| Breast | 80 (26.8) | 159 (53.4) | 4 (1.3) | |
| Colorectal | 41 (52.6) | 26 (33.3) | 1 (1.3) | |
| Leukaemia/lymphoma | 43 (53.8) | 18 (22.5) | 1 (1.3) | |
| Gynaecological | 16 (61.5) | 5 (19.2) | 0 (0.0) | |
| Urological | 22 (20.6) | 59 (55.1) | 2 (1.9) | |
|
| ||||
| Medical oncologists | 29 (24.2) | 70 (58.3) | 2 (1.7 | |
| Radiation oncologists | 22 (44.0) | 15 (30.0) | 0 (0.0) | |
| Haematologists | 31 (52.5) | 11 (18.6) | 0 (0.0) | |
| Paediatric oncologists | 5 (45.5) | 4 (36.4) | 1 (9.1) | |
| Surgeons | 115 (33.0) | 167 (47.9) | 5 (1.4) |
d.f.=degrees of freedom.
**P<0.01.
% of doctors who reported the role >50% of their patients preferred.
Univariate analyses of usual DM approach by doctor characteristics
|
|
| ||
|---|---|---|---|
|
| |||
| Medical oncologists | 42 (33.9) | 82 (66.1) | |
| Radiation oncologists | 24 (48.0) | 26 (52.0) | |
| Surgeons | 118 (33.8) | 231 (66.2) | |
| Haematologists | 32 (52.5) | 29 (47.5) | |
| Paediatric oncologists | 8 (66.7) | 4 (33.3) | |
|
| |||
| Breast | 99 (32.9) | 202 (67.1) | |
| Colorectal | 42 (53.8) | 36 (46.2) | |
| Leukaemia/lymphoma | 44 (53.0) | 39 (47.0) | |
| Gynaecological | 16 (59.3) | 11 (40.7) | |
| Urological | 23 (21.5) | 84 (78.5) | |
|
| |||
| Breast and urological | 122 (29.9) | 286 (70.1) | |
| Colorectal, gynaecology, and haematology | 102 (54.3) | 86 (45.7) | |
|
| |||
| Male | 198 (39.9) | 298 (60.1) | |
| Female | 26 (26.0) | 74 (74.0) | |
|
| |||
| Under 40 years | 25 (29.4) | 60 (70.6) | |
| 40–55 years | 125 (39.2) | 194 (60.8) | |
| Over 55 years | 73 (38.2) | 118 (61.8) | |
|
| |||
| Australia | 195(36.4) | 341 (63.6) | |
| Other | 27(46.6) | 31 (53.4) | |
|
| |||
| 2 or less | 38 (47.5) | 42 (52.5) | |
| 3–6 | 90 (39.6) | 137 (60.4) | |
| 7–10 | 56 (38.4) | 90 (61.6) | |
| 11+ | 37 (27.0) | 100 (73.0) | |
|
| |||
| <20 hrs | 63 (38.0) | 103 (62.0) | |
| 20+hrs | 127 (34.2) | 244 (65.8) | |
|
| |||
| <100 000 | 12 (30.0) | 28 (70.0) | |
| 100 000–500 000 | 63 (34.8) | 118 (65.2) | |
| 500 000+ | 115 (36.5) | 200 (63.5) | |
d.f.=degrees of freedom.
*P<0.05, **P<0.01.
Multivariate Logistic Regression predicting usual approach to decision-making
|
|
|
|
|
|---|---|---|---|
| Age | 0.00 (0.14) | 1.00 (0.75–1.33) | |
|
| |||
| Australia | 0.42 (0.30) | 1.52 (0.85–2.74) | |
| Other | |||
|
| |||
| 0–2 | 1— | ||
| 3–6 | 0.53 (0.27) | 1.71 (1.00–2.92) | |
| 7–10 | 0.57 (0.29) | 1.77 (0.99–3.14) | |
| >11 | 1.03 (0.31) | 2.81 (1.54–5.16) | |
|
| |||
| Colorectal, gynaecology, and haematological | |||
| Breast and urological | 1.10 (0.19) | 3.02 (2.08–4.37) | |
|
| |||
| Male | 1— | ||
| Female | 0.63 (0.26) | 1.87 (1.13–3.10) | |
AOR=adjusted odds ratio; d.f.=degrees of freedom; 95% CI=95% confidence interval.
*P<0.05, **P<0.01.
Univariate analyses of high comfort levels with SDMa
|
|
| |
|---|---|---|
|
| ||
| Medical oncologists | 105 (89.0) | |
| Radiation oncologists | 39 (78.0) | |
| Haematologists | 4 (66.7) | |
| Paediatric oncologists | 9 (81.8) | |
| Surgeons | 296 (84.3) | |
|
| ||
| Breast and urological | 360 (87.6) | |
| Colorectal, gynaecology and haematology | 93 (74.4) | |
|
| ||
| Male | 372 (83.0) | |
| Female | 81 (92.0) | |
|
| ||
| Under 40 years | 65 (86.7) | |
| 40–55 years | 241 (83.4) | |
| Over 55 years | 146 (84.6) | |
|
| ||
| Australia | 412 (84.4) | |
| Other | 39 (84.8) | |
|
| ||
| 2 or less | 62 (81.6) | |
| 3–6 | 162 (80.6) | |
| 7–10 | 111 (86.7) | |
| 11+ | 113 (90.4) | |
|
| ||
| <20 hrs | 137 (82.5) | |
| 20+hrs | 315 (85.4) | |
|
| ||
| <100 000 | 34 (85.0) | |
| 100 000–500 000 | 158 (86.8) | |
| 500 000+ | 259 (83.0) | |
*P<0.05 **P<0.01.
Percentages here represent respondents who reported comfort levels of 4 or 5 on the 5-point Likert scale, 1=not comfortable, 5=very comfortable.
An initial decision to shorten the survey for participants other than breast cancer specialists, excluding the question concerning comfort levels with each of the four decision making examples was reversed mid-way through sending the survey to second cohort (haematologists) and explains the small number of responses in this group for these questions.
Multivariate logistic regression predicting high comfort with SDM
|
|
|
|
|
|---|---|---|---|
|
| |||
| Colorectal, gynaecology, and haematological | |||
| Breast and urological | 0.93 (0.26) | 2.53 (1.52–4.24) | |
|
| |||
| 0–2 | |||
| 3–6 | 0.10 (0.35) | 1.11 (0.55–2.22) | |
| 7–10 | 0.56 (0.40) | 1.76 (0.80–3.88) | |
| >11 | 0.84 (0.43) | 2.33 (1.00–5.44) | |
|
| |||
| Male | 1– | ||
| Female | 0.84 (0.42) | 2.31 (1.01–5.27) | |
AOR=adjusted odds ratio; d.f.=degrees of freedom; 95% CI=95% confidence interval.
*P<0.05, **P<0.01.
Discrepancy between high comfort level and reported use of SDM
|
|
|
| |
|---|---|---|---|
|
| |||
| Breast | 202 (67.1) | 266 (86.9) | 19.8 |
| Colorectal | 36 (46.2) | 51 (67.1) | 20.9 |
| Leukaemia/lymphoma | 39 (47.0) | 18 (81.8) | 34.8 |
| Gynaecological | 11 (40.7) | 24 (88.9) | 48.2 |
| Urological | 84 (81.6) | 94 (89.5) | 7.9 |
|
| |||
| Medical oncologists | 91 (65.0) | 105 (89.0) | 24.0 |
| Radiation oncologists | 26 (50.0) | 39 (78.0) | 28.0 |
| Haematologists | 29 (47.5) | 4 (66.7) | 19.2 |
| Paediatric oncologists | 4 (28.6) | 9 (81.8) | 53.2 |
| Surgeons | 231 (69.2) | 296 (84.3) | 15.1 |